New Chemistry Strategy Bypassed Cancer Cell Barriers
Researchers developed a method that could help drugs reach tumor targets that were previously difficult to treat.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you believe new medical delivery technologies will significantly improve future cancer treatment outcomes?
Scientists have developed a binding-to-release chemistry strategy that allows cancer therapies to release payloads directly at the cell surface. This approach is designed to treat tumors that have cell surface antigens which do not internalize well, potentially expanding the range of effective cancer therapies.
Why it matters
Many existing antibody-drug conjugates rely on cell surface antigens to internalize, but many cancer-specific antigens are poor at this process. This new strategy circumvents the need for internalization, which could enable better treatment options for cancers that have historically been resistant to drug delivery.
In a preclinical study, researchers demonstrated the potential of a binding-to-release (BTR) chemistry strategy using tumor models. This preliminary evidence suggests the approach successfully enables payload delivery without the requirement for target internalization.
The players
Wen et al.
The research team that authored the study detailing the binding-to-release chemistry strategy.
The details
Most current drug-conjugate therapies require the target cell to internalize the drug to release the payload inside. The new BTR chemistry strategy modifies this by enabling the drug to release its payload while still at the cell surface. By bypassing the need for endocytosis, this method aims to overcome the significant hurdle of cancer cells that possess poorly-internalized surface antigens.
Timeline
The research describing the BTR chemistry strategy was published in September 2026.
Health Landscape
Current cancer therapies like antibody-drug conjugates have revolutionized treatment, yet they remain limited by their reliance on target internalization. This development offers a new mechanism that potentially expands the utility of drug conjugates to a wider array of surface targets.
This development is currently in the early research phase and is not yet available for patient care. Because this is a preclinical finding, it is worth keeping an eye on future clinical trial announcements if you or a loved one are exploring targeted therapy options with your oncologist.
The takeaway
The binding-to-release strategy represents an important shift in how we might eventually deliver drugs to previously inaccessible tumor targets. Readers should continue to discuss emerging treatment protocols and clinical trial eligibility with their oncology team.
Further reading
For more on the current state of targeted oncological treatments, explore our full Cancer section.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe new medical delivery technologies will significantly improve future cancer treatment outcomes?
